Hepacor CZ study
Introduction
The Hepacor CZ study is conducted in order to describe the relationship between risk groups and the carrier of hepatitis C virus (HCV) in the Czech Republic.
Brief description of the study:
The study is coducted out in order to describe the relationship between risk groups and the carrier of hepatitis C virus (HCV) in the Czech Republic.
The study involves:
- MEDIREX GROUP ACADEMY n.o. as a “Party implementing the research project”
- 15 – 20 centers – health care providers in the field of general medicine and internal medicine in the Czech Republic as “investigators”.
The study gradually included 700 patients who met the study’s admission and exclusion criteria. The enrolled patient provides his/her medical history data with a focus on risk factors for HCV infection, as well as blood samples are collected for the detection of antibodies to the hepatitis C virus (HCV).
The determination of anti-HCV antibodies by chemiluminescent microparticle immunoassay (CMIA) is used in the project for the primary detection of hepatitis C virus carriers. Positive findings are subsequently confirmed by evidence using the HCV RNA by PCR (Polymerase chain reaction).
Anamnestic data, as well as test results, are recorded in the eCRF system and subsequently evaluated. No drug is validated in the study. This study is for observational purposes only and the schedule of outpatient visits, and all treatment regimens are determined by the attending physician in accordance with standard clinical practice.